Deleted Tweets From Scott Gottlieb, R-D.C.

With the product-specific guidances posted today, #FDA is making sure its policies and regulations keep pace with the evolving science of developing complex generics so patients have access to affordable medicines https://t.co/bdMNOgXFzs

RT @SGottliebFDA: Bayer’s decision to halt sales of the Essure device follows FDA’s patient safety action in April that restricted sa… https://t.co/00X5oQAnoL

RT @medpagetoday: .@US_FDA Commissioner @SGottliebFDA pitched his agency's plan for increasing competition in the biosimilar market.… https://t.co/kGaqb2RNel

RT @US_FDA: There are both risks and potential benefits of flavored tobacco products. @FDATobacco is exploring the public healt… https://t.co/BYr4dExsmZ

Bayer’s decision to halt sales of Essure device follows #FDA’s patient safety action in April that restricted sale and distribution of Essure; postmarket safety review will continue to be priority for us; we’ll keep women informed https://t.co/1uZR329oHP https://t.co/H3SSwXIHnP

RT @SeemaCMS: #ICYMI. Watch our E/M Coding Reform discussion from earlier this week & learn about the significant impact behind o… https://t.co/QqVAXFBga0

#FDA released new guidance on developing drugs to treat resistant hypertension. Severe, resistant hypertension remains an unmet medical need for many patients, and a significant source of morbidity. We're committed to advancing innovations to help patients https://t.co/CbemkX9gRh

@angelicalavito Looks like you might have hit most of the major food groups https://t.co/n7DkC8EyLv

#FDA is taking new policy steps to facilitate greater access by enabling a broader range of drugs to be moved from Rx to over-the-counter; empowering consumers and lowering healthcare costs https://t.co/bfpbZrtC08

RT @SGottliebFDA: Bayer’s decision to halt sales of Essure device follows #FDA’s patient safety action in April that restricted sale… https://t.co/VsxXi7zsIA

To advance the development of generic drugs we posted 43 product-specific guidances to give regulatory clarity for generic sponsors. We're on track to break our 2017 record number of generic drug approvals, with a new all time record for 2018 https://t.co/bdMNOgXFzs

RT @NPF: We appreciate the leadership of @SGottliebFDA and @US_FDA on the newly released Biosimilars Action Plan:… https://t.co/gI5AaQfmcF

Among our efforts, one approach: the possible development of a public-private partnership – a CyberMed Safety Analysis Board - to complement existing device vulnerability and response mechanisms and serve as a resource for device makers and #FDA

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device and earlier agency actions

Medical device safety is a key #FDA priority. We’re committed to protecting U.S. patients by minimizing avoidable risks, assuring they have timely information to make well-informed decisions, and advancing devices that are safer, more effective, and address unmet medical need. https://t.co/Dm73SQ213p

We'll integrate #FDA’s premarket and post-market activities through a reorganization in our medical device centers, creating a broader and deeper view of device safety, effectiveness and quality across the total product life cycle. Patient Safety is at the center of these efforts https://t.co/msK4BH9BPQ

Our aim: ensure that devices not only meet the gold standard for getting to market but continue to meet this standard as we get more data and learn more about their benefit-risk profile in real-world settings. These new approaches will also help advance beneficial innovation

As the #FDA learned more from patients about the serious adverse events associated with this device, we took a series of important actions to better understand the benefits and risks, and to address patient safety concerns. https://t.co/SUxrXJcVsD

RT @FDAOncology: #FDAOncology Perspective: Metastasis-free Survival—A New End Point in #ProstateCancer Trials @NEJM #pcsm https://t.co/qS6wjI3twh

To advance development of generic drugs #FDA issued 43 product-specific guidances to lay out the path for copying important, off patent drugs. We're on track to break our 2017 record number of generic drug approvals, with a new all time record for 2018 https://t.co/vFS7tBbdTA https://t.co/TAWXquVxyg

With the product-specific guidances posted today, #FDA is making sure its policies and regulations keep pace with the evolving science of developing complex generics so patients have access to affordable medicines https://t.co/bdMNOgXFzs

RT @SGottliebFDA: Bayer’s decision to halt sales of the Essure device follows FDA’s patient safety action in April that restricted sa… https://t.co/00X5oQAnoL

RT @medpagetoday: .@US_FDA Commissioner @SGottliebFDA pitched his agency's plan for increasing competition in the biosimilar market.… https://t.co/kGaqb2RNel

RT @US_FDA: There are both risks and potential benefits of flavored tobacco products. @FDATobacco is exploring the public healt… https://t.co/BYr4dExsmZ

Bayer’s decision to halt sales of Essure device follows #FDA’s patient safety action in April that restricted sale and distribution of Essure; postmarket safety review will continue to be priority for us; we’ll keep women informed https://t.co/1uZR329oHP https://t.co/H3SSwXIHnP

RT @SeemaCMS: #ICYMI. Watch our E/M Coding Reform discussion from earlier this week & learn about the significant impact behind o… https://t.co/QqVAXFBga0

#FDA released new guidance on developing drugs to treat resistant hypertension. Severe, resistant hypertension remains an unmet medical need for many patients, and a significant source of morbidity. We're committed to advancing innovations to help patients https://t.co/CbemkX9gRh

@angelicalavito Looks like you might have hit most of the major food groups https://t.co/n7DkC8EyLv

#FDA is taking new policy steps to facilitate greater access by enabling a broader range of drugs to be moved from Rx to over-the-counter; empowering consumers and lowering healthcare costs https://t.co/bfpbZrtC08

RT @SGottliebFDA: Bayer’s decision to halt sales of Essure device follows #FDA’s patient safety action in April that restricted sale… https://t.co/VsxXi7zsIA

To advance the development of generic drugs we posted 43 product-specific guidances to give regulatory clarity for generic sponsors. We're on track to break our 2017 record number of generic drug approvals, with a new all time record for 2018 https://t.co/bdMNOgXFzs

RT @NPF: We appreciate the leadership of @SGottliebFDA and @US_FDA on the newly released Biosimilars Action Plan:… https://t.co/gI5AaQfmcF

Among our efforts, one approach: the possible development of a public-private partnership – a CyberMed Safety Analysis Board - to complement existing device vulnerability and response mechanisms and serve as a resource for device makers and #FDA

On Friday, Bayer said the permanent birth control device Essure would no longer be sold or distributed in the US for commercial reasons after 12/31/18. This came after FDA’s patient safety action in April restricting sale and distribution of the device and earlier agency actions

Medical device safety is a key #FDA priority. We’re committed to protecting U.S. patients by minimizing avoidable risks, assuring they have timely information to make well-informed decisions, and advancing devices that are safer, more effective, and address unmet medical need. https://t.co/Dm73SQ213p

We'll integrate #FDA’s premarket and post-market activities through a reorganization in our medical device centers, creating a broader and deeper view of device safety, effectiveness and quality across the total product life cycle. Patient Safety is at the center of these efforts https://t.co/msK4BH9BPQ

Our aim: ensure that devices not only meet the gold standard for getting to market but continue to meet this standard as we get more data and learn more about their benefit-risk profile in real-world settings. These new approaches will also help advance beneficial innovation

As the #FDA learned more from patients about the serious adverse events associated with this device, we took a series of important actions to better understand the benefits and risks, and to address patient safety concerns. https://t.co/SUxrXJcVsD

RT @FDAOncology: #FDAOncology Perspective: Metastasis-free Survival—A New End Point in #ProstateCancer Trials @NEJM #pcsm https://t.co/qS6wjI3twh

To advance development of generic drugs #FDA issued 43 product-specific guidances to lay out the path for copying important, off patent drugs. We're on track to break our 2017 record number of generic drug approvals, with a new all time record for 2018 https://t.co/vFS7tBbdTA https://t.co/TAWXquVxyg